Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699410 | 0.94 | CASP3 (0.51) | L3MBTL1CASP3SENP7SENP8SENP6 | |
| SCHEMBL29699451 | 0.81 | METAP2 (0.39) | L3MBTL1CASP3SENP7NPC1RAB9A | |
| SCHEMBL23457557 | 0.81 | METAP2 (0.39) | L3MBTL1CASP3SENP7NPC1RAB9A | |
| SCHEMBL6161532 | 0.80 | NPC1 (0.47) | L3MBTL1CASP3SENP7SENP8SENP6 | |
| SCHEMBL23457476 | 0.80 | NPC1 (0.39) | CASP3SENP7NPC1RAB9ACYP1A2 | |
| SCHEMBL29699517 | 0.76 | GRM4 (0.40) | CASP3SENP7NPC1RAB9ACYP1A2 | |
| SCHEMBL23457511 | 0.76 | GRM4 (0.40) | CASP3SENP7NPC1RAB9ACYP1A2 | |
| SCHEMBL30574683 | 0.75 | CCR1 (0.34) | IDO1 | |
| SCHEMBL31393744 | 0.68 | ALPL (0.43) | NPC1RAB9ACYP1A2IDO1 | |
| SCHEMBL22608567 | 0.68 | L3MBTL1 (0.44) | L3MBTL1CASP3SENP7SENP8SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | L3MBTL1 1830/4885CASP3 2910/4885SENP7 2842/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | L3MBTL1 1685/4885CASP3 3148/4885SENP7 3012/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | L3MBTL1 1830/4885CASP3 2910/4885SENP7 2842/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | L3MBTL1 1830/4885CASP3 2910/4885SENP7 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.